WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages

BACKGROUND: Although the standard treatment for the patients with recurrent and metastatic prostate cancer (CaP) is androgen deprivation therapy, castration-resistant prostate cancer (CRPC) eventually emerges. Our previous report indicated that bone morphogenetic protein 6 (BMP6) induced CRPC via tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Geun Taek, Kwon, Seok Joo, Kim, Jongmyung, Kwon, Young Suk, Lee, Nara, Hong, Jeong Hee, Jamieson, Christina, Kim, Wun-Jae, Kim, Isaac Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846063/
https://www.ncbi.nlm.nih.gov/pubmed/29381686
http://dx.doi.org/10.1038/bjc.2017.451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846063/
https://www.ncbi.nlm.nih.gov/pubmed/29381686
http://dx.doi.org/10.1038/bjc.2017.451

Ejemplares similares